Navigation Links
Pangu BioPharma, aTyr Pharma's Subsidiary in Hong Kong, Files Three Patent Applications
Date:6/29/2009

aTyr Pharma Targets for Novel Biotherapeutics Based On Naturally Resected tRNA Synthetases

SAN DIEGO, June 29 /PRNewswire/ -- Pangu BioPharma, a subsidiary of aTyr Pharma in Hong Kong, today announced the filing of its third patent application on proprietary, naturally occurring, resected human tRNA synthetases. Although tRNA synthetases are universal and essential components of protein synthesis machinery found in all organisms, human synthetases have naturally occurring resected variants with potent cell signaling activities that are vital to normal functioning of humans. The work at Pangu BioPharma is focused on identifying and characterizing new examples of the tRNA synthetases resectome. In just the first year of operations, Pangu BioPharma has built a strong patent portfolio that provides fundamental components of aTyr Pharma's portfolio of biotherapeutic candidates that can be used to treat a wide variety of diseases, such as cardiovascular, neurological and metabolic disorders.

Pangu BioPharma is the result of an innovative partnership between aTyr Pharma and the Hong Kong University of Science and Technology (HKUST), with project funding from the Innovation and Technology Commission (ITC) of Hong Kong. James Cai, President of Pangu BioPharma, notes that, "Hong Kong's government and universities are working together to attract exciting drug discovery and development companies to make Hong Kong a new frontier in the biotechnology industry. We based Pangu BioPharma here in Hong Kong in order to capitalize on this unique position in Asia as well as to tap into the highly educated population and support of new technology industries. We are very excited about the productivity and the science being generated by the scientists in our labs here in Hong Kong, and believe that HKUST has been an essential partner in generating this mutual success."

According to Jeff Watkins, CEO of aTyr Pharm
'/>"/>

SOURCE aTyr Pharma
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. CB1400, Patented by Canopus BioPharma, Enters Phase II Clinical Trials for the Prevention of Mucositis in Patients With Cancer of the Head and Neck
2. DOR BioPharma, Inc. Executes $400,000 Equity Investment Agreement With Numoda Corporation
3. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
4. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
5. Pharmasset Commences Dosing in Phase 3 Registration Studies of Clevudine for HBV
6. Pharmasset Commences Dosing in 28-Day Combination Study of R7128 with Pegasys(R) plus Copegus(R) for Hepatitis C
7. Pharmasset Announces Clevudine and R7128 Presentations at HEP-DART
8. Pharmasset Announces R7128 Achieves 85% Rapid Virologic Response in a 4-week Combination Study for the Treatment of Chronic Hepatitis C
9. Roche and Pharmasset To Present the R7128 Monotherapy Resistance Profile
10. Pharmasset Reports First Fiscal Quarter 2008 Financial Results
11. Pharmasset Presents Results of 4-Week Combination Study of R7128 for the Treatment of Chronic Hepatitis C
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/15/2014)... 15, 2014  Over 200 patients, families, physicians ... to learn, interact and participate in the drive ... Lupus Trials Fair launched by the Lupus ... Lupus Foundation .  Attendees interacted directly with researchers ... experiences, ideas and needs and learning about more ...
(Date:9/15/2014)... 2014 Biomerics LLC, a leading provider ... announced its merger with Access Point Technologies and ... division was formed to provide next generation catheter ... structure heart, interventional radiology, interventional cardiology, and neurovascular ... will be led by Steve Berhow , ...
(Date:9/15/2014)... 2014 Chek Diagnostics, the U.S.-based manufacturer of ... point-of-care diagnostic products, has again been named to the ... companies in America. The Inc. 5000 ranking ... Chek Diagnostics earned its place on the list by ... 2013. For Chek Diagnostics, who appears on ...
Breaking Medicine Technology:Lupus Research Institute Launches NYC's First Lupus Trials Fair 2Lupus Research Institute Launches NYC's First Lupus Trials Fair 3Biomerics and Access Point Technologies OEM Announce Merger and Creation of Biomerics Advanced Catheter Division 2Chek Diagnostics Named to Inc. Magazine's 5000 Fastest Growing Private Companies List for the Fourth Time 2Chek Diagnostics Named to Inc. Magazine's 5000 Fastest Growing Private Companies List for the Fourth Time 3
(Date:9/15/2014)... News) -- Births of multiple babies cost more and ... births, researchers report. The researchers suggest that limiting ... could ease some of that burden. Over the ... with births to older mothers and use of assisted ... New South Wales, Australia. Their study, published online ...
(Date:9/15/2014)... 15, 2014 As Colorado's historic ... its first full year, there are a variety ... in the evolution of its marketing and branding. ... taken by Denver's Kindman, one of the state's ... , Kindman has pioneered the first-ever branded and ...
(Date:9/15/2014)... September 15, 2014 According to a ... Market - Global Industry Analysis, Size, Share, Growth, Trends ... was valued at USD 12,212.9 million in 2013 and ... at a CAGR of 7.2% from 2014 to 2020. ... properties of light within specific electromagnetic spectrum to identify ...
(Date:9/15/2014)... New York (PRWEB) September 15, 2014 ... in U.S. courts, Bernstein Liebhard LLP notes that a ... be useful in curbing aggression in children with ADHD ... and parent training in behavioral management techniques. According to ... children with ADHD and aggression problems, half of whom ...
(Date:9/15/2014)... Adding chest radiation to chemotherapy allows some people with ... rates by nearly 50 percent, European researchers report. ... researchers recommended that chest radiotherapy be routinely offered to ... chemotherapy. , , Small-cell lung cancer (SCLC) is an ... 13 percent of all lung cancers. For most people, ...
Breaking Medicine News(10 mins):Health News:Study Ties Multiple Births to Higher Costs, Complications 2Health News:Study Ties Multiple Births to Higher Costs, Complications 3Health News:Colorado Company Unveils Innovative Line of Pre-packaged Cannabis Products 2Health News:Colorado Company Unveils Innovative Line of Pre-packaged Cannabis Products 3Health News:Spectrometry Market Expected to Reach USD 19.6 Billion Globally in 2020: Transparency Market Research 2Health News:Spectrometry Market Expected to Reach USD 19.6 Billion Globally in 2020: Transparency Market Research 3Health News:Spectrometry Market Expected to Reach USD 19.6 Billion Globally in 2020: Transparency Market Research 4Health News:Spectrometry Market Expected to Reach USD 19.6 Billion Globally in 2020: Transparency Market Research 5Health News:Risperdal News: Bernstein Liebhard LLP Notes New Study Regarding Risperdal and Children with ADHD 2Health News:Risperdal News: Bernstein Liebhard LLP Notes New Study Regarding Risperdal and Children with ADHD 3Health News:Risperdal News: Bernstein Liebhard LLP Notes New Study Regarding Risperdal and Children with ADHD 4Health News:Chest Radiation May Help Fight Some Advanced Lung Cancers: Study 2Health News:Chest Radiation May Help Fight Some Advanced Lung Cancers: Study 3
... finds these doctors have better results, including survival rates ... surgeons may be the best choice for adults requiring ... study suggests. , A congenital heart defect occurs when ... vessels near the heart. , The researchers analyzed a ...
... researchers from,Wayne State University, in collaboration with Basrah Medical ... New Iraqi Journal of,Medicine today on war-related mental health ... Bengt B. Arnetz, Ph.D., professor of Family Medicine and ... State University led the team,of researchers to conduct a ...
... cardiac valves years later , , FRIDAY, Nov. 7 (HealthDay News) ... help fight obesity has been tied to heart value damage ... a new study reports. , The appetite suppressant fenfluramine ... of its links to heart damage. Thousands of lawsuits have ...
... Triple-S,Management Corporation (NYSE: GTS ) today ... Officer, and Juan-Jose Roman,Finance Vice President & CFO, ... Credit Suisse 2008 Healthcare Conference in Phoenix on,November ... presentation will be,broadcast live through the Internet. You ...
... by a tumor or injury carry a severe psychological and ... in plastic surgery. Helmut Fischer and Wolfgang Gubisch present the ... of Deutsches rzteblatt International ( Dtsch Arztebl Int ... a woman who had had a tumor removed from the ...
... Events Held in Los Angeles Area Enable Medicare,Beneficiaries ... Period, SAN FRANCISCO, Nov. 7 Helping ... of California is offering,free "Fitness and Flexibility" events ... month. The events will offer a demonstration of ...
Cached Medicine News:Health News:Pediatric Heart Surgeons May Be Best Choice for Adults 2Health News:First Study of War-Related Mental Disorders Among Iraqis 10 Years Post-Gulf War Published by Researchers at Wayne State University and Basrah University, Iraq 2Health News:Banned Obesity Drug Tied to Heart Risks Long After Use 2Health News:Triple-S Management Corporation to Present at Credit Suisse 2008 Healthcare Conference 2Health News:Medicare Beneficiaries Can Suit Up, Sweat, and Learn About Blue Shield's Medicare Advantage Plans at Local Malls and Senior Centers 2Health News:Medicare Beneficiaries Can Suit Up, Sweat, and Learn About Blue Shield's Medicare Advantage Plans at Local Malls and Senior Centers 3Health News:Medicare Beneficiaries Can Suit Up, Sweat, and Learn About Blue Shield's Medicare Advantage Plans at Local Malls and Senior Centers 4Health News:Medicare Beneficiaries Can Suit Up, Sweat, and Learn About Blue Shield's Medicare Advantage Plans at Local Malls and Senior Centers 5
Relocatable frame has been designed specifically for fractionated stereotactic radiotherapy treatments. It provides a fast, non-invasive and reproducible fixation of the patient....
The unique MR-frame and its indicators are made of a highly tensile and fibre reenforced Epoxyd material....
VG2 PLIF (Parallel) Posterior lumbar interbody fusion. Frozen preservation. Consists of two outer cortical planks, center cancellous plank, all from the same donor, held together by two press-fit cor...
An all-cortical structure provides the structural benefits of cortical bone. Precision machined to exact specifications to promote healthy lordosis and vertebral body distraction....
Medicine Products: